TABLE 2.

Effect of the conditioning biofeedback on the amplitude of the EMG envelopes.

Subject #	TA (mean (SD)	VL (mean (SD)	GM (mean (SD)
1	1.74 ± 1.03*	0.10 ± 0.31	0.22 ± 0.31*
2	4.94 ± 3.06*	0.16 ± 0.34*	0.82 ± 0.61*
3	0.57 ± 0.29*	1.81 ± 0.66*	2.15 ± 0.83*
4	1.26 ± 0.76*	0.87 ± 0.33*	5.12 ± 1.51*
5	4.10 ± 1.04*	1.10 ± 0.50*	3.86 ± 0.95*
6	3.78 ± 1.18*	0.98 ± 0.47*	2.86 ± 1.21*
7	3.49 ± 1.40*	0.30 ± 0.25*	0.14 ± 0.80
8	2.29 ± 0.97*	1.37 ± 0.52*	2.10 ± 0.91*
9	3.48 ± 1.03*	1.38 ± 0.67*	3.81 ± 2.39*
10	2.95 ± 0.75*	0.64 ± 0.70*	2.89 ± 1.54*
Mean ± SD across all subjects	2.86 ± 1.15	0.87 ± 0.47	2.40 ± 1.10

Values indicate the difference in peak amplitude between the POST and PRE trial, normalized with respect to the PRE trial mean amplitude (e.g., a value of 1 corresponds to a change in amplitude of 100%, meaning that the amplitude of POST peaks populations was two times the mean amplitude of the PRE trial). Statistically significant values are indicated with an asterisk (p-value < 0.05 in the t-test). Only values from target muscles are reported.